Overview: Why Retatrutide Results Matter
Retatrutide (LY3437943) has produced the most significant weight reduction results of any metabolic peptide tested in clinical trials to date. Developed by Eli Lilly as a triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide achieved a mean body weight reduction of -24.2% at its highest dose over 48 weeks — surpassing both semaglutide and tirzepatide in their respective pivotal trials.
These results are drawn from peer-reviewed publications in the New England Journal of Medicine and The Lancet. This article summarizes the key clinical trial findings, metabolic outcomes, body composition data, and safety profile that define retatrutide’s position in the research landscape. For a detailed breakdown of retatrutide’s mechanism and receptor pharmacology, see our Retatrutide Triple-Agonist Research Guide.
Phase 2 Obesity Trial Results (Jastreboff et al., 2023)
The landmark Phase 2 trial enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Participants were randomized to placebo or one of six retatrutide dose cohorts and treated for 48 weeks.
Weight loss results by dose
| Dose Cohort | Mean Weight Loss (%) | Mean Weight Loss (kg) | % Achieving ≥15% Loss |
|---|---|---|---|
| Placebo | -2.1% | -2.2 kg | 3% |
| 1mg | -8.7% | -9.2 kg | 19% |
| 4mg (escalated) | -17.1% | -18.2 kg | 56% |
| 8mg (escalated) | -22.1% | -23.5 kg | 75% |
| 12mg (escalated) | -24.2% | -26.3 kg | 83% |
The most striking finding was that the 12mg cohort had not reached a weight loss plateau at 48 weeks — the weight loss curves were still declining, suggesting even greater reductions with extended treatment. This contrasts with semaglutide, which typically reaches plateau around 60-68 weeks.
What these numbers mean in context
A -24.2% mean weight reduction translates to approximately 58 lbs (26.3 kg) for a 240 lb participant. For perspective, bariatric surgery (gastric bypass) typically produces 25-35% weight loss — retatrutide at its maximum dose is approaching surgical-level outcomes through pharmacological intervention alone. In the 12mg cohort, 83% of participants achieved at least 15% weight loss, and more than half exceeded 25%.
How Retatrutide Results Compare to Other GLP-1 Compounds
| Compound | Trial | Duration | Max Weight Loss | Plateau Reached? |
|---|---|---|---|---|
| Retatrutide 12mg | Phase 2 | 48 weeks | -24.2% | No |
| Tirzepatide 15mg | SURMOUNT-1 | 72 weeks | -22.5% | Approaching |
| Semaglutide 2.4mg | STEP 1 | 68 weeks | -16.0% | Yes |
| Liraglutide 3.0mg | SCALE | 56 weeks | -8.0% | Yes |
Retatrutide achieved greater weight loss in a shorter timeframe than any other compound, and it hadn’t plateaued. The comparison isn’t perfectly controlled — these are separate trials with different populations — but the magnitude of difference is noteworthy. For a deeper comparison, see our Semaglutide vs Retatrutide vs Tirzepatide Comparison.
The Glucagon Effect: Why Retatrutide Outperforms
The key differentiator in retatrutide’s results is the glucagon receptor activation — a pathway absent from semaglutide and tirzepatide. GLP-1 and GIP reduce food intake through appetite suppression and gastric slowing. Glucagon adds a third mechanism: increased energy expenditure through hepatic lipid oxidation and thermogenesis.
In simpler terms, semaglutide and tirzepatide primarily reduce caloric intake (you eat less). Retatrutide reduces caloric intake AND increases caloric output (you eat less and burn more). This dual-direction approach explains why retatrutide achieved greater weight loss in a shorter period without participants reaching a metabolic plateau where the body adapts and weight loss stalls.
Metabolic Outcomes Beyond Weight Loss
The clinical trials measured several metabolic parameters beyond body weight:
Glycemic control (Type 2 diabetes trial — Rosenstock et al., 2023)
A separate Phase 2 trial in participants with type 2 diabetes (published in The Lancet) demonstrated significant improvements in glucose metabolism. Mean HbA1c reductions ranged from -1.3% to -2.0% depending on dose — comparable to the most effective diabetes medications available. Fasting glucose levels improved across all dose groups, and insulin sensitivity markers showed meaningful improvement.
Liver fat reduction
In a substudy of the obesity trial, participants treated with retatrutide 8mg and 12mg showed dramatic reductions in liver fat content. At 48 weeks, the mean relative reduction in liver fat exceeded 80% in the highest dose groups. Among participants who met criteria for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) at baseline, more than 80% in the 8mg and 12mg cohorts no longer met those criteria after treatment — effectively resolving their fatty liver disease.
Cardiovascular markers
Across dose cohorts, retatrutide treatment was associated with improvements in multiple cardiovascular risk factors including reductions in waist circumference, blood pressure, and triglyceride levels, with increases in HDL cholesterol. These improvements correlated with the degree of weight loss.
Body Composition Data
One of the critical questions with any weight loss intervention is the composition of weight lost — specifically, what proportion is fat mass versus lean mass. In the Phase 2 trial, body composition was assessed using dual-energy X-ray absorptiometry (DEXA) in a subset of participants.
The data showed that approximately 75-80% of weight lost was fat mass, with 20-25% being lean mass. This ratio is consistent with — and may be slightly more favorable than — the body composition changes seen with semaglutide and tirzepatide. The preservation of lean mass is believed to be supported by retatrutide’s GIP receptor activity, which has been linked to muscle protein synthesis pathways in preclinical research.
Safety Profile
The most common adverse events across all trials were gastrointestinal in nature, with incidence increasing at higher doses:
- Nausea: 6-31% (dose-dependent), primarily during escalation periods
- Diarrhea: 6-25%, generally mild to moderate
- Vomiting: 0-16%, occurring mainly in the first weeks of each dose increase
- Decreased appetite: 3-19%, which contributed to the weight reduction effect
- Constipation: 3-12%, consistent with GLP-1 receptor-mediated gastric slowing
Serious adverse events were rare across all cohorts. Discontinuation rates due to adverse events ranged from 0-6% depending on the dose group, which is comparable to or lower than rates seen with semaglutide (7% in STEP 1) and tirzepatide (4-7% in SURMOUNT-1).
For a comprehensive overview of peptide-associated side effects, see our Peptide Side Effects: What Researchers Should Know.
Phase 3 Trials: What to Expect
Eli Lilly initiated Phase 3 clinical trials for retatrutide in 2024 under the TRIUMPH program. These larger, longer-duration studies will provide more definitive efficacy and safety data. Key Phase 3 trials include:
- TRIUMPH-1: Retatrutide for obesity without type 2 diabetes
- TRIUMPH-2: Retatrutide for type 2 diabetes
- TRIUMPH-3: Retatrutide for obesity with type 2 diabetes
- TRIUMPH-4: Retatrutide for metabolic dysfunction-associated steatohepatitis (MASH)
Results from these trials are expected between 2025 and 2027. If Phase 3 results confirm the Phase 2 findings, retatrutide could receive FDA approval as early as 2027-2028.
Reconstitution for Research Use
PSPeptides carries research-grade retatrutide in multiple vial sizes (5mg, 10mg, 20mg, and 30mg), manufactured in the US with 99%+ purity verified via independent HPLC and mass spectrometry. Each vial comes with a batch-specific Certificate of Analysis.
For reconstitution instructions, see our How to Reconstitute Peptides Guide. For exact dosage volume calculations, use our free Peptide Reconstitution Calculator. For reconstitution, you’ll need Hospira Bacteriostatic Water and sterile laboratory syringes.
Frequently Asked Questions
How much weight can retatrutide help lose?
In Phase 2 clinical trials, the highest dose (12mg weekly) produced a mean weight loss of -24.2% over 48 weeks. At that point, weight was still declining — the curve had not plateaued, suggesting even greater reductions may be possible with longer treatment.
Is retatrutide more effective than semaglutide?
Based on available clinical data, retatrutide produced significantly greater weight loss (-24.2% at 48 weeks) than semaglutide (-16.0% at 68 weeks) in their respective trials. However, these are separate trials with different populations and cannot be directly compared with the same certainty as a head-to-head study.
When will retatrutide be FDA approved?
Phase 3 trials are underway through the TRIUMPH program. If results are positive, FDA approval could come as early as 2027-2028. Currently, retatrutide is available only as a research compound.
Are retatrutide results permanent?
Weight regain after discontinuation of GLP-1 class medications is well-documented — the STEP 1 extension trial showed that most weight lost on semaglutide was regained within a year of stopping treatment. Similar patterns are expected with retatrutide, though specific discontinuation data has not yet been published.
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526.
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023;402(10401):529-544.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(4):327-340.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
Buy Research-Grade Retatrutide — From $39.99 →
This content is for educational and research purposes only. All products are intended for laboratory research use only. Not for human consumption.